Article
The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research - 6 Jan 2026
Botticelli Andrea, Cremolini Chiara, Scagnoli Simone, Biffoni Mauro, Lonardi Sara, Fornaro Lorenzo, Guarneri Valentina, De Giorgi Ugo, Ascierto Paolo Antonio, Blandino Giovanni, D'Amati Giulia, Aglietta Massimo, Conte Pierfranco, Crimini Edoardo, Ceracchi Maurizio, Pisegna Simona, Verkhovskaia Sofia, Bordonaro Roberto, Bracarda Sergio, Butturini Giovanni, Del Mastro Lucia, DeCensi Andrea, Fabbri Agnese, Fenocchio Elisabetta, Gori Stefania, Metro Giulio, Pessino Annamaria, Pozzessere Daniele, Puglisi Fabio, Tamberi Stefano, Zambelli Alberto, Marino Donatella, Capoluongo Ettore, Cappuzzo Federico, Cerbelli Bruna, Giannini Giuseppe, Malapelle Umberto, Mazzuca Federica, Nuti Marianna, Pruneri Giancarlo, Simmaco Maurizio, Strigari Lidia, Tonini Giuseppe, Martini Nello, Curigliano Giuseppe, Marchetti Paolo
Abstract excerpt
PURPOSE: This analysis evaluated the influence of tissue and liquid biopsy concordance on outcomes in patients enrolled in the ROME trial. PATIENTS AND METHODS: The ROME trial, a phase II multicenter study, enrolled 1,794 patients with advanced solid tumors. Next-generation sequencing was performed on tissue and liquid biopsies using FoundationOne CDx and FoundationOne Liquid CDx. A centralized molecular tumor...
Read the complete abstract on PubMed